<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00153582</url>
  </required_header>
  <id_info>
    <org_study_id>HaemaCBFWT102</org_study_id>
    <secondary_id>Carreras 04/25f</secondary_id>
    <nct_id>NCT00153582</nct_id>
  </id_info>
  <brief_title>WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      In this trial, HLA-A2+ patients with active AML are vaccinated with a peptide from the
      leukemia-associated antigen WT1 together with immunological adjuvants keyhole limpet
      hemocyanin (KLH) as T-helper protein and granulocyte macrophage colony stimulating factor
      (GM-CSF) 4 times bi-weekly, then monthly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II trial HLA-A2+ patients with active AML without curative treatment option are
      vaccinated with WT1 126-134 peptide mixed with adjuvant KLH as T-helper protein and GM-CSF 4
      times bi-weekly, then monthly.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Generation of T cell response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment>25</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>WT1 126-134 peptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AML or myelodysplastic syndromes (MDS)

          -  Partial response (PR) or complete response (CR) or smoldering course without option
             for allogeneic stem cell transplantation

          -  HLA-A2+

          -  WT1-expression in bone marrow
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Keilholz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmen Scheibenbogen, MD</last_name>
    <phone>+49-30-8445-4576</phone>
    <email>carmen.scheibenbogen@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology&amp;Oncology Charité CBF</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Keilholz, MD</last_name>
      <phone>+49-30-8445-3906</phone>
      <email>ulrich.keilholz@charite.de</email>
    </contact>
    <investigator>
      <last_name>Ulrich Keilholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Mailänder V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004 Jan;18(1):165-6.</citation>
    <PMID>14603333</PMID>
  </results_reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>February 21, 2006</last_update_submitted>
  <last_update_submitted_qc>February 21, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

